Induction of Long-Lasting Regulatory B Lymphocytes by Modified Immune Cells in Kidney Transplant Recipients

ABSTRACT: Background: We recently demonstrated that donor-derived modified immune cells (MICs)-PBMCs that acquire immunosuppressive properties after a brief treatment-induced specific immunosuppression against the allogeneic donor when administered before kidney transplantation. We found up to a 68-fold increase in CD19 + CD24 hi CD38 hi transitional B lymphocytes compared with transplanted controls. Methods: Ten patients from a phase 1 clinical trial who had received MIC infusions before kidney transplantation were followed to post-transplant day 1080. Results: Patients treated with MICs had a favorable clinical course, showing no donor-specific human leukocyte antigen antibodies or acute rejections. The four patients who had received the highest dose of MICs 7 days before surgery and were on reduced immunosuppressive therapy showed an absence of in vitro lymphocyte reactivity against stimulatory donor blood cells, whereas reactivity against third party cells was preserved. In these patients, numbers of transitional B lymphocytes were 75-fold and seven-fold higher than in 12 long-term survivors on minimal immunosuppression and four operationally tolerant patients, respectively ( P <0.001 for both). In addition, we found significantly higher numbers of other regulatory B lymphocyte subsets and a gene expression signature suggestive of operational tolerance in three of four patients. In MIC-treated patients, in vitro lymphocyte reactivity against donor blood cells was restored after B lymphocyte depletion, suggesting a direct pathophysiologic role of regulatory B lymphocytes in donor-specific unresponsiveness. Conclusions: These results indicate that donor-specific immunosuppression after MIC infusion is long-lasting and associated with a striking increase in regulatory B lymphocytes. Donor-derived MICs appear to be an immunoregulatory cell population that when administered to recipients before transplantation, may exert a beneficial effect on kidney transplants. Clinical trial registry name and registration number: MIC Cell Therapy for Individualized Immunosuppression in Living Donor Kidney Transplant Recipients (TOL-1), NCT02560220.

• Autores: Álvarez Botero, Cristiam Mauricio; Morath, Christian; Schaier, Matthias; Ibrahim, Eman; Wang, Lei; Kleist, Christian; Opelz, Gerhard; Süsal, Caner; Ponath, Gerald; Aly, Mostafa; Kälble, Florian; Speer, Claudius; Benning, Louise; Nusshag, Christian; Pego da Silva, Luiza; Sommerer, Claudia; Hückelhoven Krauss, Angela; Czock, David; Mehrabi, Arianeb; Schwab, Constantin; Waldherr, Rüdiger; Schnitzler, Paul; Merle, Uta; Tran, ThuongHien; Scherer, Sabine; Böhmig, Georg A.; Müller Tidow, Carsten; Reiser, Jochen; Zeier, Martin; Schmitt, Michael; Terness, Peter; Schmitt, Anita; Daniel, Volker
• Tipo de recurso: Article of investigation
• Fecha de publicación: 2023
• Institución: Universidad de Antioquia
• Repositorio: Repositorio UdeA
• Idioma: eng
• OAI Identifier: oai:bibliotecadigital.udea.edu.co:10495/40180
• Acceso en línea: https://hdl.handle.net/10495/40180
• Palabra clave: Linfocitos B Reguladores; B-Lymphocytes, Regulatory; Tolerancia Inmunológica; Immune Tolerance; Terapia de Inmunosupresión; Immunosuppression Therapy; Inmunosupresores; Immunosuppressive Agents; Trasplante de Riñón; Kidney Transplantation; Receptores de Trasplantes; Transplant Recipients; https://id.nlm.nih.gov/mesh/D060151; https://id.nlm.nih.gov/mesh/D007108; https://id.nlm.nih.gov/mesh/D007165; https://id.nlm.nih.gov/mesh/D007166; https://id.nlm.nih.gov/mesh/D016030; https://id.nlm.nih.gov/mesh/D066027
• Rights: openAccess
• License: An error occurred getting the license - uri.